2023
Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric‐Onset IBD Cohort
Kaplan J, Liu C, King E, Bass J, Patel A, Tung J, Chen S, Lissoos T, Candela N, Saeed S, Colletti R, Network I, Adler J, Baron H, Cabrera J, Dorsey J, Dykes D, Ebach D, Garin‐Laflam M, Gold B, Grunow J, Higuchi L, Jester T, Lapsia S, Leibowitz I, Linvlle T, Morhardt T, Moses J, Moulton D, Nasiri‐Blomgren S, Niklinska‐Schirtz B, Ogunmola N, Palomo P, Park K, Pashankar D, Pasternak B, Radano M, Samson C, Sandberg K, Schaefer M, Shashidhar H, Steiner S, Sullivan J, Tomer G, Verstraete S. Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric‐Onset IBD Cohort. Journal Of Pediatric Gastroenterology And Nutrition 2023, 76: 566-575. PMID: 36804501, PMCID: PMC10097486, DOI: 10.1097/mpg.0000000000003734.Peer-Reviewed Original ResearchConceptsCrohn's diseaseUlcerative colitisLoss of responseFirst biologicSubsequent biologicsBiologic agentsBiologic medicationsBiologic treatmentAnti-tumor necrosis factor agentsUpper gastrointestinal tract involvementGastrointestinal tract involvementNecrosis factor agentsActive Crohn's diseaseFirst biologic agentIBD cohortInitial biologicSecond biologicTract involvementCorticosteroid useFactor agentsPediatric IBDBiologic initiationDisease courseUnivariate analysisSevere disease
2017
OP025 Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn's disease in clinical practice
King E, Park K, Pashankar D, Shashidhar H, Sudel B, Eichner S, Chen S, Pratt J, Colletti R, Burlington I. OP025 Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn's disease in clinical practice. Journal Of Crohn's And Colitis 2017, 11: s15-s16. DOI: 10.1093/ecco-jcc/jjx002.024.Peer-Reviewed Original ResearchSteroid-free clinical remissionSteroid-free clinical responseDisease activity indexClinical remissionClinical responseCrohn's diseaseClinical practiceATNF therapyCare visitsDisease patientsShort Pediatric Crohn's Disease Activity IndexAnti-tumor necrosis factor agentsExact testPediatric Crohn's Disease Activity IndexPediatric Crohn's disease patientsCrohn's Disease Activity IndexMultivariable logistic regression analysisConcomitant immunomodulator therapyNecrosis factor agentsPhysician global assessmentRetrospective cohort studyPediatric Crohn's diseaseCrohn's disease patientsNumber of patientsDuration of treatment